Au nanoparticles functionalized 3D-MoS2 nanoflower: An efficient SERS matrix for biomolecule sensing

Singha, Shib Shankar; Mondal, Suchanda; Bhattacharya, Tara Shankar; Das, Laboni; Sen, Kamalika; Satpati, Biswarup; Das, Kaustuv; Singha, Achintya

doi:10.1016/j.bios.2018.07.061

Cited by 103 publications

(55 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholesterol may be considered as a reference in this field, since high levels in blood (> M) [58] may be related to cardiovascular diseases. Raman spectroscopy has been successfully applied for the detection of cholesterol in pathologic samples [59] and, most recently, in cells using arquitectured SERS substrates [60,61]. AuCu NPs were used as SERS substrates to collect spectra of cholesterol (10 -8 M) under excitation line of 514 nm (Fig.…”

Section: (A) Cholesterolmentioning

confidence: 99%

Cu@Au self-assembled nanoparticles as SERS-active substrates for (bio)molecular sensing

Cabello

Nwoko

Marco

et al. 2019

Journal of Alloys and Compounds

View full text Add to dashboard Cite

Cu 0 (core)-Au 0 (shell) (Cu@Au) bimetallic nanoparticles (NPs) synthesized under microwaveassisted heating were interrogated for surface enhanced Raman scattering (SERS)-active substrates. NPs characterization, by XRD, XPS and UV/vis spectroscopy, showed the formation of self-assembled particles with the occurrence of electron transfer from Cu to Au and the absence of CuxO. TEM and AF4 demonstrated NPs with a mean diameter of 4.7 nm. Despite the low LSPR shown by small nanoparticles (< 10 nm diameter), our Cu@Au NPs showed enhanced SERS effect, demonstrated by the calculated scattering signal enhancement factor (3 x 10 5 ), which may be related to electromagnetic coupling. Selected examples of analytes of interest, including some biomolecules, were studied to demonstrate the versatility of our Cu@Au NPs as SERS-active substrates.

show abstract

Section: (A) Cholesterolmentioning

confidence: 99%

Cu@Au self-assembled nanoparticles as SERS-active substrates for (bio)molecular sensing

Cabello

Nwoko

Marco

et al. 2019

Journal of Alloys and Compounds

View full text Add to dashboard Cite

show abstract

“…Magnetoresis- The dynamic range can be enhanced by increasing the surface area of the sensing. The larger surface area can be engineered by using three-dimensional (3D) sensing structures, such as nanopillar or nanoflower arrays, to improve the area for the occupancy of the biorecognition elements [78][79][80], thereby improving the probability to detect high concentrations of the target. However, when developing detection strategies for clinical biomarkers, what will determine the valid dynamic range is the cutoff value (threshold) of the interested biomarkers (explained in detail in Section 4).…”

Section: Dynamic Rangementioning

confidence: 99%

The Challenges of Developing Biosensors for Clinical Assessment: A Review

et al. 2021

View full text Add to dashboard Cite

Emerging research in biosensors has attracted much attention worldwide, particularly in response to the recent pandemic outbreak of coronavirus disease 2019 (COVID-19). Nevertheless, initiating research in biosensing applied to the diagnosis of diseases is still challenging for researchers, be it in the preferences of biosensor platforms, selection of biomarkers, detection strategies, or other aspects (e.g., cutoff values) to fulfill the clinical purpose. There are two sides to the development of a diagnostic tool: the biosensor development side and the clinical side. From the development side, the research engineers seek the typical characteristics of a biosensor: sensitivity, selectivity, linearity, stability, and reproducibility. On the other side are the physicians that expect a diagnostic tool that provides fast acquisition of patient information to obtain an early diagnosis or an efficient patient stratification, which consequently allows for making assertive and efficient clinical decisions. The development of diagnostic devices always involves assay developer researchers working as pivots to bridge both sides whose role is to find detection strategies suitable to the clinical needs by understanding (1) the intended use of the technology and its basic principle and (2) the preferable type of test: qualitative or quantitative, sample matrix challenges, biomarker(s) threshold (cutoff value), and if the system requires a mono- or multiplex assay format. This review highlights the challenges for the development of biosensors for clinical assessment and its broad application in multidisciplinary fields. This review paper highlights the following biosensor technologies: magnetoresistive (MR)-based, transistor-based, quartz crystal microbalance (QCM), and optical-based biosensors. Its working mechanisms are discussed with their pros and cons. The article also gives an overview of the most critical parameters that are optimized by developing a diagnostic tool.

show abstract

“…The dynamic range can be enhanced by increasing the surface area of the sensing. The larger surface area can be engineered by using three-dimensional (3D) sensing structures, such as nanopillars or nanoflowers arrays to improve the area for the occupancy of the biorecognition elements [78][79][80].…”

Section: Dynamic Rangementioning

confidence: 99%

The challenges of developing biosensors for clinical assessment: a review

Prabowo¹

2021

Preprint

View full text Add to dashboard Cite

Emerging research in biosensors has attracted much attention worldwide, particularly in re-sponse to the recent pandemic outbreak of coronavirus disease 2019 (COVID-19). Neverthe-less, initiating research in biosensing applied to the diagnostic of diseases is still challenging for researchers, either from the preferences of biosensor platforms, selection of biomarkers, detection strategies, and other aspects (e.g., cutoff values) to fulfill the clinical purpose. There are two sides to the development of a diagnostic tool: the biosensor development side and the clinical side. From the development side, the research engineers seek the typical characteristics of a biosensor: sensitivity, selectivity, linearity, stability, and reproducibility. On the other side are the physicians that expect a diagnostic tool that provides fast acquisition of patient in-formation to obtain an early diagnostic or an efficient patient stratification, which conse-quently allows making assertive and efficient clinical decisions. The development of diagnostic devices always involves assay developer researchers, working as pivots to bridge both sides, which role is to find detection strategies suitable to the clinical needs. First, by understanding the intended use of the technology and its basic principle; second, the preferable type of test: qualitative or quantitative, sample matrix challenges, biomarker(s) threshold (cutoff value), and if the system requires a mono or multiplex assay format. This review highlights the challenges for the development of biosensors for clinical assessment and its broad application in multidisciplinary fields. This review paper highlights the following biosensor technologies: magnetoresistive (MR)-based, transistor-based, quartz crystal microbalance (QCM), and op-tical-based biosensors. Its working mechanisms are discussed with their pros and cons. The article also gives an overview of the most critical parameters that are optimized by developing a diagnostic tool.

show abstract

Au nanoparticles functionalized 3D-MoS2 nanoflower: An efficient SERS matrix for biomolecule sensing

Cited by 103 publications

References 74 publications

Cu@Au self-assembled nanoparticles as SERS-active substrates for (bio)molecular sensing

Cu@Au self-assembled nanoparticles as SERS-active substrates for (bio)molecular sensing

The Challenges of Developing Biosensors for Clinical Assessment: A Review

The challenges of developing biosensors for clinical assessment: a review

Contact Info

Product

Resources

About